ClinicalTrials.gg
CompletedNCT01136538Updated Jun 14, 2010

Bioavailability Study of Valacycovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fed Condition

A Phase 1 interventional study of Valacyclovir Hydrochloride in Healthy, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-06-14.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to

  1. Compare and evaluate the single-dose bioavailability study of 1000mg Valacyclovir HCl tablets of Dr. Reddy's and Valtrex (R)(Valacyclovir Hydrochloride)CAPLETS 1 gram of GlaxoSmithkline, in healthy, adult human subjects under fed conditions.
  2. monitor the adverse events and ensure the safety of subjects.
Read the detailed description

An open label, balanced, randomized, two-treatment, two-sequence two-period, single-dose, crossover comparative bioavailability study of 1000 mg Valacyclovir Hydrochloride Tablets of Dr. Reddy's Laboratories Ltd., India and valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline in healthy, adult human subjects under fed conditions

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Crossover
  • Valacyclovir Hydrochloride
03

In context

Lead sponsor

Dr. Reddy's Laboratories Limited is the lead sponsor of 224 studies on the registry; 2 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The subjects were selected for study participation, based on the following criteria:

  1. Human subjects aged between 18 and 45 years (including both).
  2. Subjects' weight within the normal range according to normal values for the (18.5 to 24.9 kg/m2) with minimum of 50 kg weight.
  3. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable normal range.
  4. Subjects having normal 12-lead (ECG).
  5. Subjects having normal chest X-Ray (PIA view).
  6. Have a negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
  7. Have negative alcohol breath test.
  8. Subjects willing to adhere to the protocol requirements and to provide written .

Exclusion criteria

Exclusion Criteria:

The subjects were excluded from the study, based on the following criteria:

  1. to Valacyclovir Hydrochloride or related drugs.
  2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
  3. History or presence of significant alcoholism or drug abuse in the past one year.
  4. History or presence of significant smoking (more than 10 cigarettes or beedi' s/day).
  5. History or presence of significant asthma, urticaria or other allergic reactions.
  6. History or presence of significant gastric and/or duodenal ulceration.
  7. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumour.
  8. History or presence of cancer.
  9. Difficulty with donating blood.
  10. Difficulty in swallowing solids like tablets or capsules.
  11. Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg.
  12. Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.
  13. Pulse rate less than 50/minute or more than 100/minute.
  14. Oral temperature less than 95°F or more than 98.6°F.
  15. Respiratory rate less than 12/minute or more than 20/minute
  16. Subjects who have used any prescription medication, within 14 days of period 01 dosing or OTC medication within 14 days of period 01 dosing.
  17. Major illness during 3 months before screening.
  18. Participation in a drug research study within past 3 months.
  19. Donation of blood in the past 3 months before screening.
  20. Subjects who have consumed xanthine-containing products (including caffeine, theobromines, etc.) within 48 hours prior to period 01 dosing.
  21. Subjects who have consumed food or beverages containing grapefruit or pomelo within 14 days prior to period 01 dosing.
  22. Subjects who have used any drugs or substances known to be strong inhibitors of CYP enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first dose.
  23. Subjects who have used any drugs or substances known to be strong inducers of CYP enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first dose.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Valacyclovir Hydrochloride

    Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited

    Drug: Valacyclovir Hydrochloride

  • Active comparator
    Valtrex (R)

    Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline

    Drug: Valacyclovir Hydrochloride

Interventions

  • Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited

    Also known as: Valtrex (R)(Valacyclovir Hydrochloride) CAPLETS 1 gm

06

What researchers measure

Primary outcomes

  1. Bioequivalence based on Cmax and AUC parameters

    Time frame: 4 months

07

Study locations

1 site
  • Veeda clinical research Pvt. Ltd., India
    Ahmedabad, Gujrat 380 015, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Feb 2007 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2010
First posted
Jun 3, 2010
Start
Feb 2007
Primary completionActual
Feb 2007
CompletionActual
May 2007
Last update
Jun 14, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01136538
First posted
Jun 3, 2010
Start date
Feb 2007
Primary completion
Feb 2007
Completion
May 2007
Last update
Jun 14, 2010

Study contacts

Dr. Dharmesh Domadia, MD
principal investigator · Veeda clinical research Pvt. Ltd., India

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valacyclovir

Start the discussion